

Colon Length (cm)
(mean±SEM)
0
2
4
6
8
10
ns
*
Control
Group B
Group A
Colon Length (cm)
(mean±SD)
5
6
7
8
9
10
11
12
Control
Group B
Group A

FIG. 1




FIG. 2a



Crypts - number decrease
TBI-Vehicle
TBI-FE 203799
% animals of total
100
80
60
40
20
0
None
Minimal
Mild
Moderate
Crypts - hyperplasia
TBI-Vehicle
TBI-FE 203799
% animals of total
100
80
60
40
20
0
None
Minimal
Mild
Moderate
Villi - shortening
TBI-Vehicle
TBI-FE 203799
% animals of total
100
80
60
40
20
0
None
Minimal
Mild
Moderate
Crypts abscess
TBI-Vehicle
TBI-FE 203799
% animals of total
100
80
60
40
20
0
None
Minimal
Mild
Moderate

FIG. 2b



single cell necrosis
A B
80%
60%
40%
20%
0%
grade 1 grade 2 grade 3
necrosis of whole crypts
A B
100%
80%
60%
40%
20%
0%
grade 1 grade 2 grade 3
shortening of villi
A B
100%
80%
60%
40%
20%
0%
grade 1 grade 2 grade 3
cryptal hyperplasia (regenerative)
A B
60%
40%
20%
0%
grade 1 grade 2 grade 3
cell infiltrate
A B
100%
75%
50%
25%
0%
grade 1 grade 2
abcess, cryptal
A B
100%
75%
50%
25%
0%
grade 1 grade 2

FIG. 2c



Colon Length (cm)
(Mean±SEM)
12
11
10
9
8
7
6
5
ns
****
**
Group A
Group B
Group C
Small intestine Length (cm)
(Mean±SEM)
45
40
35
30
ns
ns
ns
Group A
Group B
Group C

FIG. 3



Engraftment Rate
MEAN±SEM - Control
MEAN±SEM - apraglutide
120,00
100,00
80,00
60,00
40,00
20,00
0,00
hCD45/ (hCD45+ mCD45)
mCD45/ (hCD45+ mCD45)
Day 7
Day 14
Day 20
Blood (D7-20)
Spleen (D20)
Bone marrow (D20)

FIG. 4



% animals of total
100
90
80
70
60
50
40
30
20
10
0
Vehicle
Apraglutide
None
Minimal
Mild
Moderate
Severity of villi-shortening

FIG. 5



A: Cytarabine model
Control/Vehicle
Cytarabine (30 mg/kg)/Apraglutide
(1,000 nmoles/kg)
Cytarabine
(30 mg/kg)/vehicle
B: Melphalan model
Vehicle
Melphalan
Melphalan + FE 203799

FIG. 6



Citrulline (μmol/L)
Mean ± SEM
100
80
60
40
20
0
Vehicle
Cytarabine
Cytarabine + Apraglutide
ns
*
*
Citrulline (μM)
Mean ± SEM
100
80
60
40
20
0
Vehicle
Melphalan
Melphalan + Apraglutide

FIG. 7



Control/vehicle
Cytarabine (D5-9)
Cytarabine+ Apraglutide (D5-18)
Cytarabine + Apraglutide (D1,3,5,8,11,14,17)
Body weight (kg)
30
27
24
21
18
15
D-16 D-17 D-15 D-14 D-5 D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 D13 D14 D15 D16 D17 D18
Days post-treatment
Cytarabine
Control/vehicle
Melphalan
Melphalan + Apraglutide (1,000 nmol/kg)
Mean weight (g)
30
29
28
27
26
25
24
23
22
21
20
-13 -10 -1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Days post-treatment
Melphalan

FIG. 8



% Survival
Days post-treatment
Control/Vehicle
Cytarabine (Day 5-9)
Cytarabine + Azaglutide (Day 1-17)
Cytarabine + Azaglutide (Day 5-17)
Cytarabine + Azaglutide (Day 1,3,5,8,11,14,17)
Melphalan
Control/Vehicle
Melphalan (17.5 mg/kg)
Melphalan (17.5 mg/kg) + Apraglutide 1,000 mcg/kg

FIG. 9



Control
Cytarabine
Cytarabine + Apraglutide
Post-treatment
Post-treatment
Post-treatment
F
B
Percentage (%)
100
80
60
40
20
0

FIG. 10a



Relative mean abundance of taxa
at the Phylum level
Taxa
(mean ± SD)
100
80
60
40
20
0
Control/vehicle
Cytarabine/vehicle
Cytarabine/apraglutide
Firmicutes (day 0)
Bacteroidetes (day 0)
Firmicutes (day 18)
Bacteroidetes (day 18)

FIG. 10b



After treatment (Day 7)
%hCD45 in bone marrow
%hCD45 in spleen
# p <0.05 relative to vehicle-only control
Vehicle-only control
Vehicle+ cytarabine
Apraglutide+ cytarabine
Treatment group

FIG. 11a



Spleen
After Treatment (Study Day 7)
%hCD45 in Spleen
0
5
10
15
20
25
#
#
vehicle-only control
vehicle+ cytarabine
FE 203799+ cytarabine
Treatment Group
Bone Marrow
Before Treatment (Study Day -6)
After Treatment (Study Day 7)
%hCD45 in Bone Marrow
0
20
40
60
80
#
#
vehicle-only control
vehicle+ cytarabine
FE 203799+ cytarabine
Treatment Group

FIG. 11b



Number of cells (10^9/L)
(mean ± SEM)
0
2
4
6
WBC
NEUT
LYMPH
Control
Cytarabine
Cytarabine + apraglutide
Cytarabine + apraglutide (recov)
ns
ns
ns
**
##
*
#

FIG. 12



Number of cells (10^9/L)
5,0
4,5
4,0
3,5
3,0
2,5
2,0
1,5
1,0
0,5
0,0
WBC
NEUT
LYMPH
Vehicle - Phase 1
Melphalan 17.5 mg/kg - Phase 1
Vehicle - Phase 2
Melphalan 17.5 mg/kg - Phase 2
Melphalan 17.5 mg/kg + FE 203709 (1000 nmol/kg) - Phase 2

FIG. 13



Survival (%)
110
100
90
80
70
60
50
40
30
20
10
0
6
8
10
12
14
Days post-transplant
TBI/BMT + FE 203799
TBI/BMT + Vehicle
TBI only
5/5
4/10
0/10

FIG. 14




FIG. 15b



FIG. 15a



Weight loss group A
Day 1
Day 2
Day 3
Day 4
Day 5
Day 6
Day 7
Day 8
Day 9
Day 10
Day 11
Day 12
Day 13
Day 14
5%
-5%
-15%
-25%
-35%
66
68
70
74
76
78
80
83
85
87

FIG. 16a



Weight loss group B
Day 1
Day 2
Day 3
Day 4
Day 5
Day 6
Day 7
Day 8
Day 9
Day 10
Day 11
Day 12
Day 13
Day 14
10%
0%
-10%
-20%
-30%
-40%
67
69
72
75
77
79
81
82
86
89

FIG. 16b



Weight loss group C
Day 1
Day 2
Day 3
Day 4
Day 5
Day 6
Day 7
Day 8
Day 9
Day 10
Day 11
Day 12
Day 13
Day 14
10%
5%
0%
-5%
-10%
-15%
-20%
-25%
-30%
-35%
71
73
84
88
90

FIG. 16c



vehicle control
FE 203799 (300 nmol/kg, qd) + cytarabine**
FE 203799 (100 nmol/kg, qd) + cytarabine**
FE 203799 (30 nmol/kg, qd) + cytarabine*
hGLP-2 (160 nmol/kg, bid) + cytarabine
vehicle + cytarabine
Fraction Survival
1.00
0.75
0.50
0.25
0.00
0
2
4
6
8
10
12
14
16
18
20
22
Time (days)
cytarabine
4 day GLP-2 agonist

FIG. 17



Body Weight (g)
22
18
14
-4
-2
0
2
4
6
8
10
12
14
16
18
20
Day
FE 203799 (30 nmol/kg, qd) + cytarabine
FE 203799 (100nmol/kg, qd) + cytarabine
FE 203799 (300nmol/kg, qd) + cytarabine
hGLP-2 (160 nmol/kg, bid) + cytarabine
vehicle + cytarabine
vehicle control

FIG. 18



Serum Citrulline
Concentration (umol/L)
0
20
40
60
80
Treatment
Control
Vehicle
GLP-2
30
100
300
FE 203799
(nmol/kg)
cytarabine
*
*
*
*#
*#

FIG. 19



Polymorphonuclear Count
(cells)
30
20
10
0
Control
Vehicle
GLP-2
30
100
300
FE 203799
(nmol/kg)
cytarabine
Treatment

FIG. 20